1. Vella A. Mechanism of action of DPP-4 inhibitors: new insights. J Clin Endocrinol Metab. 2012; 97:2626–8.
2. Godinho R, Mega C, Teixeira-de-Lemos E, Carvalho E, Teixeira F, Fernandes R, et al. The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a “me too” or “the special one” antidiabetic class? J Diabetes Res. 2015; 2015:806979.
3. Burness CB. Omarigliptin: first global approval. Drugs. 2015; 75:1947–52.
4. Krishna R, Addy C, Tatosian D, Glasgow XS, Gendrano Iii IN, Robberechts M, et al. Pharmacokinetics and pharmacodynamics of omarigliptin, a once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, after single and multiple doses in healthy subjects. J Clin Pharmacol. 2016; 56:1528–37.
5. Tsuchiya S, Friedman E, Addy C, Wakana A, Tatosian D, Matsumoto Y, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men. J Diabetes Investig. 2017; 8:84–92.
6. Chacra A, Gantz I, Mendizabal G, Durlach L, O’Neill EA, Zimmer Z, et al. A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment. Int J Clin Pract. 2017; 71:e12955.
7. Gantz I, Okamoto T, Ito Y, Sato A, Okuyama K, O’Neill EA, et al. A randomized, placebo-controlled trial evaluating the safety and efficacy of adding omarigliptin to antihyperglycemic therapies in Japanese patients with type 2 diabetes and inadequate glycemic control. Diabetes Ther. 2017; 8:793–810.
8. Gantz I, Okamoto T, Ito Y, Okuyama K, O’Neill EA, Kaufman KD, et al. A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2017; 19:1602–9.
9. Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O’Neill EA, et al. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017; 16:112.
10. Gantz I, Sokolova L, Jain L, Iredale C, O’Neill EA, Wei Z, et al. Use of prohibited medication, a potentially overlooked confounder in clinical trials: omarigliptin (once-weekly DPP4 inhibitor) monotherapy trial in 18- to 45-year-olds. Clin Ther. 2017; 39:2024–37.
11. Goldenberg R, Gantz I, Andryuk PJ, O’Neill EA, Kaufman KD, Lai E, et al. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the oncedaily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2017; 19:394–400.
12. Handelsman Y, Lauring B, Gantz I, Iredale C, O’Neill EA, Wei Z, et al. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a onceweekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017; 33:1861–8.
13. Hattori S. Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes. Diabetol Metab Syndr. 2020; 12:24.
14. Home P, Shankar RR, Gantz I, Iredale C, O’Neill EA, Jain L, et al. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. Diabetes Res Clin Pract. 2018; 138:253–61.
15. Ishii H, Kamei N, Shimono D, Niiya T, Tosaki T, Kitazawa T, et al. Treatment burden on once-weekly omarigliptin versus daily dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: randomized controlled trial (ONWARD-DPP4 Study). Diabetes Ther. 2023; 14:1639–58.
16. Kadowaki T, Seino Y, Kaku K, Okamoto T, Kameya M, Sato A, et al. A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. Diabetes Obes Metab. 2021; 23:1242–51.
17. Lee SH, Gantz I, Round E, Latham M, O’Neill EA, Ceesay P, et al. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin. BMC Endocr Disord. 2017; 17:70.
18. Ohara M, Nagaike H, Fujikawa T, Kohata Y, Ogawa M, Omachi T, et al. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: a prospective study. Diabetes Res Clin Pract. 2021; 179:108999.
19. Shankar RR, Inzucchi SE, Scarabello V, Gantz I, Kaufman KD, Lai E, et al. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017; 33:1853–60.
20. Sheu WH, Gantz I, Chen M, Suryawanshi S, Mirza A, Goldstein BJ, et al. Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes. Diabetes Care. 2015; 38:2106–14.
21. Yoshizawa Y, Hosojima M, Kabasawa H, Tanabe N, Ugamura D, Koda Y, et al. Effects of the once-weekly DPP4 inhibitor omarigliptin on glycemic control in patients with type 2 diabetes mellitus on maintenance hemodialysis: a 24-week open-label, multicenter randomized controlled study. Diabetes Ther. 2021; 12:655–67.
22. Kawasaki E, Nakano Y, Fukuyama T, Uchida A, Sagara Y, Tamai H, et al. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes. World J Diabetes. 2021; 12:2087–95.
23. Wang X, Li X, Qie S, Zheng Y, Liu Y, Liu G. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. Medicine (Baltimore). 2018; 97:e11946.
24. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–60.
26. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64:383–94.
27. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4. (updated August 2023). Chichester: John Wiley & Sons;2023. Chapter 13, Assessing risk of bias due to missing results in a synthesis [cited 2023 Dec 19]. Available from:
www.training.cochrane.org/handbook.
28. Addy C, Tatosian D, Glasgow XS, Gendrano IN 3rd, Kauh E, Martucci A, et al. Pharmacokinetic and pharmacodynamic effects of multiple-dose administration of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in obese participants with and without type 2 diabetes mellitus. Clin Ther. 2016; 38:516–30.
29. Addy C, Tatosian DA, Glasgow XS, Gendrano IN III, Sisk CM, Kauh EA, et al. Effects of age, sex, and obesity on the single-dose pharmacokinetics of omarigliptin in healthy subjects. Clin Pharmacol Drug Dev. 2016; 5:374–82.
30. Xu S, Tatosian D, Mcintosh I, Caceres M, Matthews C, Samuel K, et al. Absorption, metabolism and excretion of [14C] omarigliptin, a once-weekly DPP-4 inhibitor, in humans. Xenobiotica. 2018; 48:584–91.
31. Jain L, Chain AS, Tatosian DA, Hing J, Passarell JA, Kauh EA, et al. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin. Br J Clin Pharmacol. 2019; 85:2759–71.
32. Tosaki T, Kamiya H, Yamamoto Y, Himeno T, Kato Y, Kondo M, et al. Efficacy and patient satisfaction of the weekly DPP-4 inhibitors trelagliptin and omarigliptin in 80 Japanese patients with type 2 diabetes. Intern Med. 2017; 56:2563–9.
33. Dutta D, Mohindra R, Surana V, Sharma M. Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: a meta-analysis. Diabetes Metab Syndr. 2022; 16:102469.
34. Huang J, Jia Y, Sun S, Meng L. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol Toxicol. 2020; 21:68.
35. Ling J, Cheng P, Ge L, Zhang DH, Shi AC, Tian JH, et al. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetol. 2019; 56:249–72.
36. Florentin M, Kostapanos MS, Papazafiropoulou AK. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World J Diabetes. 2022; 13:85–96.